dcc-3116
deciphera
['agent', 'dcc-3116', 'deciphera']
deciphera pharmaceuticals, inc. presents initial phase 1 single agent dose escalation data for first-in-class ulk inhibitor of autophagy, dcc-3116, at the european society for medical oncology (esmo) congress 2022 
Breaking news from Business Wire